Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $6.5 million.

  • Zevra Therapeutics' Cash from Financing Activities fell 8991.74% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 8805.09%. This contributed to the annual value of $82.1 million for FY2024, which is 18846.26% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Cash from Financing Activities stood at $6.5 million, which was down 8991.74% from $1.4 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Cash from Financing Activities high stood at $74.3 million for Q1 2021, and its period low was -$4.7 million during Q1 2022.
  • For the 5-year period, Zevra Therapeutics' Cash from Financing Activities averaged around $12.7 million, with its median value being $1.6 million (2025).
  • Within the past 5 years, the most significant YoY rise in Zevra Therapeutics' Cash from Financing Activities was 718333.33% (2021), while the steepest drop was 613913.04% (2021).
  • Zevra Therapeutics' Cash from Financing Activities (Quarter) stood at -$2.9 million in 2021, then surged by 88.68% to -$325000.0 in 2022, then skyrocketed by 1639.69% to $5.0 million in 2023, then tumbled by 84.09% to $796000.0 in 2024, then soared by 720.35% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $1.4 million for Q2 2025, and $1.6 million during Q1 2025.